Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23,509 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Synthetic lethality-mediated precision oncology via the tumor transcriptome.
Lee JS, Nair NU, Dinstag G, Chapman L, Chung Y, Wang K, Sinha S, Cha H, Kim D, Schperberg AV, Srinivasan A, Lazar V, Rubin E, Hwang S, Berger R, Beker T, Ronai Z, Hannenhalli S, Gilbert MR, Kurzrock R, Lee SH, Aldape K, Ruppin E. Lee JS, et al. Among authors: lee sh. Cell. 2021 Apr 29;184(9):2487-2502.e13. doi: 10.1016/j.cell.2021.03.030. Epub 2021 Apr 14. Cell. 2021. PMID: 33857424 Free PMC article.
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor.
Kim Y, Kim CH, Lee HY, Lee SH, Kim HS, Lee S, Cha H, Hong S, Kim K, Seo SW, Sun JM, Ahn MJ, Ahn JS, Park K. Kim Y, et al. Among authors: lee sh, lee hy, lee s. J Thorac Oncol. 2019 Sep;14(9):1608-1618. doi: 10.1016/j.jtho.2019.05.033. Epub 2019 Jun 11. J Thorac Oncol. 2019. PMID: 31195179 Free article.
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH, Cha H, Shim JH, Lee B, Chung J, Lee C, Kim NKD, Choi YL, Hwang S, Lee Y, Park S, Jung HA, Kim JY, Park YH, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH, Park WY. Hong TH, et al. Among authors: lee sh, lee y, lee c, lee b. J Immunother Cancer. 2020 Oct;8(2):e001199. doi: 10.1136/jitc-2020-001199. J Immunother Cancer. 2020. PMID: 33077514 Free PMC article.
Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.
Kim M, Ku JH, Kwak C, Kim HH, Lee E, Keam B, Kim TM, Heo DS, Lee SH, Moon KC. Kim M, et al. Among authors: lee e, lee sh. PLoS One. 2015 Jul 22;10(7):e0133371. doi: 10.1371/journal.pone.0133371. eCollection 2015. PLoS One. 2015. PMID: 26200905 Free PMC article. Clinical Trial.
23,509 results
You have reached the last available page of results. Please see the User Guide for more information.